Phenytoin-induced toxic epidermal necrolysis: A case report

Clinical and Experimental Dermatology

Volumn 21, Issue 2, 1996, Pages 116-120

  Creamer, J D ^a   Whittaker, S J ^a   Kerr Muir, M ^b   Smith, N P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYDAMINE; BETAMETHASONE; CHLORAMPHENICOL; FLUCLOXACILLIN; HYDROCORTISONE; HYDROXYZINE; IMIPENEM; PHENYTOIN;

ADULT; ARTICLE; CASE REPORT; EPILEPSY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS;

ADULT; ANTICONVULSANTS; EPIDERMAL NECROLYSIS, TOXIC; EYE DISEASES; HUMANS; MALE; PHENYTOIN;

EID: 0029939473     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1996.tb00032.x     Document Type: Article

References (30)

1. Bastuji-Garin S, Rzany B, Stern RS et al. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
2. Revuz J, Penso D, Roujeau J-C et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5.
3. Roujeau J-C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S.
4. Kaufman DW. Epidemiologic approaches to the study of toxic epidermal necrolysis. J Invest Dermatol 1994; 102: 31S-33S.
5. Guillaume JC, Roujeau J-C, Revuz J et al. The culprit drug in 87 cases of toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 1987; 123: 1166-70.
6. Roujeau J-C, Chosidow O, Saiag P et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
7. Saiag P, Caumes E, Chosidow O et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-74.
8. Shear NH, Spielberg SP, Grant DM et al. Differences in metabolism of sulphonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
9. Villada G, Roujeau J-C, Clerici T et al. Immunopathology of toxic epidermal necrolysis. Arch Dermatol 1992; 128: 50-3.
10. Houwerzijl J, De Gast GC, Nater JP et al. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29: 272-7.
11. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10, 11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82: 110-15.
12. Friedman PS, Strickland I, Pirmohamed M et al. Investigations of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598-604.
13. Miyauchi H, Hosokawa H, Akaeda T et al. T-cell subsets in drug-induced toxic epidermal necrolysis: possible pathogenic mechanism induced by CD 8-positive T cells. Arch Dermatol 1991; 127: 851-5.
14. Correia O, Delgado L, Ramos JP et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis, further evidence of CD 8+ lymphocyte involvement. Arch Dermatol 1993; 129: 466-8.
15. Roujeau J-C, Revuz J. Toxic epidermal necrolysis: an expanding field of knowledge. J Am Acad Dermatol 1994; 31: 301-2.
16. Roujeau J-C, Revuz J. Intensive care in dermatology. In: Champion RH, Pye RJ, eds. Recent Advances in Dermatology, Vol. 8. Edinburgh, London: Churchill Livingstone, 1990: 85-99.
17. Halebian PH, Corder VJ, Madden MR et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12.
18. Kamanabroo D, Schmitz-Langraf W, Czarnetzki BM. Plasma-pheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121: 1548-9.
19. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. J Am Acad Dermatol 1991; 25: 778-86.
20. Dasco CD, Luterman A, Curreri PW. Systemic antibiotic treatment in burned patients. Surg Clin North Am 1987; 67: 57-68.
21. Revuz J, Roujeau J-C, Guillaume JC et al. Treatment of toxic epidermal necrolysis, Creteil's experience. Arch Dermatol 1987; 123: 1156-8.
22. Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy. J Rheumatol 1983; 10: 512-13.
23. Goens J, Song M, Fondu P et al. Haematological disturbances and immune mechanisms in toxic epidermal necrolysis. Br J Dermatol 1986; 114: 255-9.
24. Roujeau J-C. Exogenous triggers. In: Wojnarowska F, Briggaman RA, eds. Management of Blistering Diseases. London: Chapman and Hall Medical, 1990: 241-62.
25. Dasgupta A, O'Malley J, Mallya R, Williams JG. Bronchial obstruction due to respiratory mucosal sloughing in toxic epidermal necrolysis. Thorax 1994; 49: 935-6.
26. Wilkins J, Morrison L, White CR. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Clin 1992; 10: 571-82.
27. Foster CS, Fong LP, Azar et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988; 95: 453-62.
28. Fabbri P, Panconesi E. Erythema multiforme ('minus' and 'maius') and drug intake. Clin Dermatol 1993; 11: 479-89.
29. Chosidow O, Delchier J-C, Chaumette M-T et al. Intestinal involvement in drug-induced toxic epidermal necrolysis (letter). Lancet 1991; 337: 928.
30. DeFelice GP, Caroli R, Antelitano A. Long-term complications of toxic epidermal necrolysis (Lyell's disease): Clinical and histopathologic study. Ophthalmologica 1987; 195: 1-6.